Pérez-Méndez Oscar, Duhal Nathalie, Lacroix Brigitte, Bonte Jean-Paul, Fruchart Jean-Charles, Luc Gérald
Department of Atherosclerosis, INSERM U545, Institut Pasteur de Lille, Lille, France.
Clin Chim Acta. 2006 Jun;368(1-2):149-54. doi: 10.1016/j.cca.2005.12.038. Epub 2006 Feb 17.
Lipoprotein lipase (LPL) deficiency has been suggested as a cause of low HDL-cholesterol (HDL-C) plasma levels, by a mechanism that involves an enhanced catabolism of HDL apolipoprotein (apo) AI. To verify the role of 2 different LPL gene mutations on HDL metabolism, we studied the in vivo turnover of the apo AI and apo AII in heterozygous carriers of LPL deficiency.
Apo AI and AII kinetics were studied by a 10-h primed constant infusion of 5,5,5-2H3-leucine approach in 2 carriers, 1 man (patient 1) and 1 woman (patient 2), and 5 control subjects. The rates of HDL apolipoproteins production (PR) and catabolism (FCR) were estimated using a one-compartment model-based analysis.
Both carriers had low HDL-C plasma levels and only patient 1 was hypertriglyceridemic. VLDL apo B was 4-times slower in patient 1 as compared to patient 2. The FCRs of apo AI in both carriers was within the range of the controls (0.200, 0.221 and 0.211+/-0.051 day(-1), respectively). Apo AII FCR in patient 1 was about 20% lower than the mean of the control group whereas being normal in patient 2. Apo AI PR in patient 1 (9.20 mg kg(-1) day(-1)) was below the lowest value in controls (range, 10.52-13.24 mg kg(-1) day(-1)) whereas in patient 2 it was normal. Apo AII PR in both patients was similar to controls.
The heterozygous carriers of 2 different mutations in the LPL gene had different VLDL apo B FCR, and from normal to slightly low HDL apolipoprotein FCR and PR. These results disagree with the putative enhanced apo AI FCR in LPL deficient patients and suggest the need to reconsider the effects of LPL activity on HDL metabolism.
脂蛋白脂肪酶(LPL)缺乏被认为是血浆高密度脂蛋白胆固醇(HDL-C)水平降低的一个原因,其机制涉及HDL载脂蛋白(apo)AI分解代谢增强。为了验证两种不同的LPL基因突变对HDL代谢的作用,我们研究了LPL缺乏杂合子携带者体内apo AI和apo AII的周转率。
采用10小时5,5,5-2H3-亮氨酸预充恒速输注法,对2名携带者(1名男性患者1和1名女性患者2)以及5名对照者进行apo AI和AII动力学研究。使用基于单室模型的分析方法估算HDL载脂蛋白的生成率(PR)和分解代谢率(FCR)。
两名携带者的血浆HDL-C水平均较低,只有患者1患有高甘油三酯血症。与患者2相比,患者1的极低密度脂蛋白apo B的代谢速度慢4倍。两名携带者体内apo AI的FCR均在对照组范围内(分别为0.200、0.221和0.211±0.051天-1)。患者1体内apo AII的FCR比对照组均值低约20%,而患者2体内的apo AII FCR正常。患者1体内apo AI的PR(9.20 mg·kg-1·天-1)低于对照组的最低值(范围为10.52 - 13.24 mg·kg-1·天-1),而患者2体内的apo AI PR正常。两名患者体内apo AII的PR与对照组相似。
LPL基因中两种不同突变的杂合子携带者具有不同的极低密度脂蛋白apo B FCR,HDL载脂蛋白FCR和PR从正常到略低。这些结果与LPL缺乏患者中推测的apo AI FCR增强不一致,提示需要重新考虑LPL活性对HDL代谢的影响。